These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 29229103)

  • 1. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
    Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
    Muro S; Sugiura H; Darken P; Dorinsky P
    Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
    Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
    Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P
    Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
    Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
    Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
    Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Reisner C; Dorinsky P
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2993-3002. PubMed ID: 31920296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
    Cazzola M; Ora J; Di Paolo A; Puxeddu E; Calzetta L; Rogliani P
    Pulm Pharmacol Ther; 2016 Aug; 39():48-53. PubMed ID: 27344046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
    Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
    Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort
    Gillen M; Forte P; Svensson JO; Lamarca R; Burke J; Rask K; Larsdotter Nilsson U; Eckerwall G
    Pulm Pharmacol Ther; 2018 Oct; 52():7-17. PubMed ID: 30077809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.
    Corren J; Korenblat PE; Miller CJ; O'Brien CD; Mezzanotte WS
    Clin Ther; 2007 May; 29(5):823-843. PubMed ID: 17697902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
    van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
    Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI.
    Murphy KR; Dhand R; Trudo F; Uryniak T; Aggarwal A; Eckerwall G
    Respir Med; 2015 Feb; 109(2):170-9. PubMed ID: 25596138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.